BUZZ-Pasithea Therapeutics rises on positive early-stage data from cancer drug

Reuters09-26

** Shares of drug developer Pasithea Therapeutics rise 64.3% to $6.31 premarket

** KTTA says its experimental cancer drug, PAS-004, was safe and well tolerated in an early-stage study

** Says one heavily pre-treated patient with stage three colon cancer showed prolonged stable disease

** Co is testing the drug in certain cancer patients whose tumor has an RAF mutation

** Says no treatment-related adverse events were observed and no drug-related dose interruptions or discontinuations

** Co expects to provide additional trial updates on a periodic basis as the trial progresses

** Up to last close, stock down 48% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment